Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)‘s stock had its “outperform” rating reiterated by research analysts at Leerink Swann in a note issued to investors on Monday.
Other research analysts also recently issued reports about the stock. Robert W. Baird reissued a “buy” rating and issued a $115.00 price target on shares of Vertex Pharmaceuticals in a report on Monday, January 9th. Jefferies Group LLC reissued a “buy” rating and issued a $102.00 price target on shares of Vertex Pharmaceuticals in a report on Wednesday, November 30th. Maxim Group reissued a “hold” rating on shares of Vertex Pharmaceuticals in a report on Tuesday, January 17th. Zacks Investment Research raised shares of Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and set a $83.00 price target for the company in a report on Tuesday, December 27th. Finally, Vetr downgraded shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $85.33 price target for the company. in a report on Tuesday, December 6th. One research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and thirteen have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $100.39.
Vertex Pharmaceuticals (NASDAQ:VRTX) traded down 0.66% during mid-day trading on Monday, reaching $91.31. The company had a trading volume of 1,351,803 shares. The firm’s market capitalization is $22.68 billion. The firm has a 50-day moving average price of $89.12 and a 200 day moving average price of $85.20. Vertex Pharmaceuticals has a 12-month low of $71.46 and a 12-month high of $103.73.
Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings data on Wednesday, January 25th. The pharmaceutical company reported $0.35 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.29 by $0.06. The company earned $458.71 million during the quarter, compared to the consensus estimate of $453.40 million. Vertex Pharmaceuticals had a negative net margin of 6.76% and a negative return on equity of 2.15%. During the same period last year, the firm earned $0.17 EPS. Analysts expect that Vertex Pharmaceuticals will post $1.62 EPS for the current year.
Your IP Address:
In other Vertex Pharmaceuticals news, Director Joshua S. Boger sold 8,000 shares of the business’s stock in a transaction dated Wednesday, January 11th. The shares were sold at an average price of $82.48, for a total value of $659,840.00. Following the transaction, the director now owns 276,225 shares in the company, valued at $22,783,038. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Joshua S. Boger sold 6,500 shares of the business’s stock in a transaction dated Wednesday, December 21st. The shares were sold at an average price of $74.16, for a total transaction of $482,040.00. Following the completion of the transaction, the director now owns 274,725 shares in the company, valued at approximately $20,373,606. The disclosure for this sale can be found here. In the last quarter, insiders sold 27,500 shares of company stock worth $2,126,370. 1.90% of the stock is owned by corporate insiders.
Several institutional investors have recently added to or reduced their stakes in the stock. Camber Capital Management LLC purchased a new position in Vertex Pharmaceuticals during the fourth quarter worth about $55,253,000. Elkhorn Investments LLC purchased a new position in Vertex Pharmaceuticals during the fourth quarter worth about $635,000. Norges Bank purchased a new position in Vertex Pharmaceuticals during the fourth quarter worth about $127,564,000. WFG Advisors LP boosted its position in Vertex Pharmaceuticals by 117,995.2% in the fourth quarter. WFG Advisors LP now owns 24,800 shares of the pharmaceutical company’s stock worth $2,188,000 after buying an additional 24,779 shares during the last quarter. Finally, Sowell Financial Services LLC purchased a new position in Vertex Pharmaceuticals during the fourth quarter worth about $245,000. Hedge funds and other institutional investors own 94.85% of the company’s stock.
Vertex Pharmaceuticals Company Profile
Vertex Pharmaceuticals Incorporated is engaged in the business of discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company operates in pharmaceuticals segment. Its business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.
Receive News & Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.